DPP-4 inhibitors: Pharmacological differences and their clinical implications

Antonio Ceriello, Liberata Sportiello, Concetta Rafaniello, Francesco Rossi

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Introduction: Recently, incretin-based therapy was introduced for the treatment of type 2 diabetes (T2D). In particular, dipeptidyl peptidase-4 inhibitors (DPP-4i) (sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin) play an increasing role in the management of T2D.Areas covered: An extensive literature search was performed to analyze the pharmacological characteristics of DPP-4i and their clinical implications.Expert opinion: DPP-4i present significant pharmacokinetic differences. They also differ in chemical structure, in the interaction with distinct subsites of the enzyme and in different levels of selectivity and potency of enzyme inhibition. Moreover, disparities in the effects on glycated hemoglobin, glucagon-like peptide-1 and glucagon levels and on glucose variability have been observed. However, indirect comparisons indicate that all DPP-4i have a similar safety and efficacy profiles. DPP-4i are preferred in overweight/obese and elderly patients because of the advantages of minimal or no influence on weight gain and low risk of hypoglycemia. For the same reasons, DPP-4i can be safely combined with insulin. However, currently cardiovascular outcomes related to DPP-4i are widely debated and the available evidence is controversial. Today, long-term studies are still in progress and upcoming results will allow us to better define the strengths and limits of this therapeutic class.

Original languageEnglish
JournalExpert Opinion on Drug Safety
Volume13
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 2014

Fingerprint

Dipeptidyl-Peptidase IV Inhibitors
Pharmacology
Type 2 Diabetes Mellitus
Incretins
Glucagon-Like Peptide 1
Glycosylated Hemoglobin A
Expert Testimony
Enzymes
Glucagon
Hypoglycemia
Weight Gain
Therapeutics
Pharmacokinetics
Insulin
Safety
Glucose

Keywords

  • Dipeptidyl peptidase-4 inhibitors
  • Glucose variability
  • Pharmacodynamics
  • Pharmacokinetics
  • Pharmacology
  • Type 2 diabetes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

DPP-4 inhibitors : Pharmacological differences and their clinical implications. / Ceriello, Antonio; Sportiello, Liberata; Rafaniello, Concetta; Rossi, Francesco.

In: Expert Opinion on Drug Safety, Vol. 13, No. SUPPL. 1, 2014.

Research output: Contribution to journalArticle

Ceriello, Antonio ; Sportiello, Liberata ; Rafaniello, Concetta ; Rossi, Francesco. / DPP-4 inhibitors : Pharmacological differences and their clinical implications. In: Expert Opinion on Drug Safety. 2014 ; Vol. 13, No. SUPPL. 1.
@article{cf2fa4e530774f0482b89c44202f4538,
title = "DPP-4 inhibitors: Pharmacological differences and their clinical implications",
abstract = "Introduction: Recently, incretin-based therapy was introduced for the treatment of type 2 diabetes (T2D). In particular, dipeptidyl peptidase-4 inhibitors (DPP-4i) (sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin) play an increasing role in the management of T2D.Areas covered: An extensive literature search was performed to analyze the pharmacological characteristics of DPP-4i and their clinical implications.Expert opinion: DPP-4i present significant pharmacokinetic differences. They also differ in chemical structure, in the interaction with distinct subsites of the enzyme and in different levels of selectivity and potency of enzyme inhibition. Moreover, disparities in the effects on glycated hemoglobin, glucagon-like peptide-1 and glucagon levels and on glucose variability have been observed. However, indirect comparisons indicate that all DPP-4i have a similar safety and efficacy profiles. DPP-4i are preferred in overweight/obese and elderly patients because of the advantages of minimal or no influence on weight gain and low risk of hypoglycemia. For the same reasons, DPP-4i can be safely combined with insulin. However, currently cardiovascular outcomes related to DPP-4i are widely debated and the available evidence is controversial. Today, long-term studies are still in progress and upcoming results will allow us to better define the strengths and limits of this therapeutic class.",
keywords = "Dipeptidyl peptidase-4 inhibitors, Glucose variability, Pharmacodynamics, Pharmacokinetics, Pharmacology, Type 2 diabetes",
author = "Antonio Ceriello and Liberata Sportiello and Concetta Rafaniello and Francesco Rossi",
year = "2014",
doi = "10.1517/14740338.2014.944862",
language = "English",
volume = "13",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Taylor and Francis Ltd.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - DPP-4 inhibitors

T2 - Pharmacological differences and their clinical implications

AU - Ceriello, Antonio

AU - Sportiello, Liberata

AU - Rafaniello, Concetta

AU - Rossi, Francesco

PY - 2014

Y1 - 2014

N2 - Introduction: Recently, incretin-based therapy was introduced for the treatment of type 2 diabetes (T2D). In particular, dipeptidyl peptidase-4 inhibitors (DPP-4i) (sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin) play an increasing role in the management of T2D.Areas covered: An extensive literature search was performed to analyze the pharmacological characteristics of DPP-4i and their clinical implications.Expert opinion: DPP-4i present significant pharmacokinetic differences. They also differ in chemical structure, in the interaction with distinct subsites of the enzyme and in different levels of selectivity and potency of enzyme inhibition. Moreover, disparities in the effects on glycated hemoglobin, glucagon-like peptide-1 and glucagon levels and on glucose variability have been observed. However, indirect comparisons indicate that all DPP-4i have a similar safety and efficacy profiles. DPP-4i are preferred in overweight/obese and elderly patients because of the advantages of minimal or no influence on weight gain and low risk of hypoglycemia. For the same reasons, DPP-4i can be safely combined with insulin. However, currently cardiovascular outcomes related to DPP-4i are widely debated and the available evidence is controversial. Today, long-term studies are still in progress and upcoming results will allow us to better define the strengths and limits of this therapeutic class.

AB - Introduction: Recently, incretin-based therapy was introduced for the treatment of type 2 diabetes (T2D). In particular, dipeptidyl peptidase-4 inhibitors (DPP-4i) (sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin) play an increasing role in the management of T2D.Areas covered: An extensive literature search was performed to analyze the pharmacological characteristics of DPP-4i and their clinical implications.Expert opinion: DPP-4i present significant pharmacokinetic differences. They also differ in chemical structure, in the interaction with distinct subsites of the enzyme and in different levels of selectivity and potency of enzyme inhibition. Moreover, disparities in the effects on glycated hemoglobin, glucagon-like peptide-1 and glucagon levels and on glucose variability have been observed. However, indirect comparisons indicate that all DPP-4i have a similar safety and efficacy profiles. DPP-4i are preferred in overweight/obese and elderly patients because of the advantages of minimal or no influence on weight gain and low risk of hypoglycemia. For the same reasons, DPP-4i can be safely combined with insulin. However, currently cardiovascular outcomes related to DPP-4i are widely debated and the available evidence is controversial. Today, long-term studies are still in progress and upcoming results will allow us to better define the strengths and limits of this therapeutic class.

KW - Dipeptidyl peptidase-4 inhibitors

KW - Glucose variability

KW - Pharmacodynamics

KW - Pharmacokinetics

KW - Pharmacology

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84907030397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907030397&partnerID=8YFLogxK

U2 - 10.1517/14740338.2014.944862

DO - 10.1517/14740338.2014.944862

M3 - Article

C2 - 25171159

AN - SCOPUS:84907030397

VL - 13

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - SUPPL. 1

ER -